The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 04, 2024

Filed:

Nov. 16, 2020
Applicant:

Nalpropion Pharmaceuticals Llc, Morristown, NJ (US);

Inventors:

Preston Klassen, La Jolla, CA (US);

Kristin Taylor, San Diego, CA (US);

Assignee:

Nalpropion Pharmaceuticals LLC, Brentwood, TN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/485 (2006.01); A61K 9/48 (2006.01); A61K 31/137 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 9/00 (2006.01); A61P 9/02 (2006.01); A61P 9/04 (2006.01); A61P 9/06 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 43/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/485 (2013.01); A61K 9/48 (2013.01); A61K 31/137 (2013.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 9/00 (2018.01); A61P 9/02 (2018.01); A61P 9/04 (2018.01); A61P 9/06 (2018.01); A61P 9/10 (2018.01); A61P 43/00 (2018.01); A61K 2300/00 (2013.01);
Abstract

The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable alts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovasular outcomes or MACE, wherein the treatment reduce, the risk of MACE.


Find Patent Forward Citations

Loading…